Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

Only about 36% of Multiple Sclerosis (MS) patients are currently treated with MS drugs

Posted Nov 17 2009 10:20pm 1 Comment
Report: Multiple Sclerosis Is The Fourth Leading Cause Of Disability Among American Women

Only about 36% of Multiple Sclerosis (MS) patients are currently treated with MS drugs, this percentage is expected to increase to 56% by 2014 as new oral MS therapies are launched

Published on July 27, 2009
by Press Office(Companiesandmarkets.com and OfficialWire )
LONDON, ENGLAND
================

Only about 36% of Multiple Sclerosis (MS) patients are currently treated with MS drugs, this percentage is expected to increase to 56% by 2014 as new oral MS therapies are launched, which shows bright opportunity for oral drugs in multiple sclerosis market. The injectables market is big but leaves certain side effects which bring the possibility for the oral drugs to succeed. It is expected that oral drugs will bring some ease for the patients. In Canada the prevalence rate of MS is the highest with closely followed by United States which is the second most affected region with increasing death rates of MS patients. Also the prevalence rate in Germany, Norway and Hungary is high. In 2008 the MS treatment market has shown good results despite the slowdown in US and with this success the probability for further growth has increased.

Gender has become a dominant factor in MS during the last decades. The studies have proved that MS prevalence rate is higher in women than men, but the cause of the disease has not been found. MS is the fourth leading cause of disability among American women. Early Age Smoking is also one of the major environmental factors which have increased the chances of MS disease. MS is slowly spreading its reach in the Asian regions. Asia can be a potential market in future.

This report analyses the global multiple sclerosis market demand and potential opportunities prevailing in the market. It gives an overview of the disease and prevalence worldwide, also covers the total market for MS treatment. It presents global MS injectable market growth and discussion of various medicines market share. The report also focuses on the growth of the industry in United States. It gives an overview of the trends and opportunities present in the industry. It also analyses competition in the market with an overview of industry players and their business strategies.

Multiple Sclerosis Treatment Market - Opportunities for Oral Drugs: http://www.companiesandmarkets.com/r.ashx?id=AY4C44X5171293

Contact: Mike King
info@companiesandmarkets.com
Tel: +44 0203 086 8600



Comments (1)
Sort by: Newest first | Oldest first
Oral Drugs might be easier to use, but have more risk that the injectables
Post a comment
Write a comment: